ERVK3-1 and glioblastoma: In addition, patients with IDH mutant GBM had significantly lower ERVK3-1 expression relative to patients with IDHwt tumors (4.57 fpkm vs. 5.19 fpkm, p < 0.0001), as did patients with 1p19q co-deletion (4.41 fpkm vs. 5.17 fpkm, p < 0.0001).